Every 8-K that Cadrenal Therapeutics, Inc. (CVKD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics, Inc. (CVKD) reported that the FDA provided positive feedback in a Type D Meeting held on July 28, 2026, aligning with the company on key elements of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT).
The FDA agreed to an optimized definition of worsening HIT for the composite primary endpoint, focusing on progression of thrombotic events or hospital discharge through Day 14, including extension of existing thrombi into new vascular segments. The agency also agreed to a placebo-controlled design, with both CAD-1005 and placebo arms receiving standard anticoagulation, and to assess bleeding using International Society on Thrombosis and Haemostasis criteria. Cadrenal highlights HIT as a ~50,000 patient acute market in the U.S. and cites a projected $2 billion peak annual revenue opportunity for CAD-1005.
Cadrenal Therapeutics, Inc. reported second quarter 2026 results and outlined progress in its Cardiac Acute Critical Care Franchise and strategic partnering efforts. For the quarter ended June 30, 2026, the company recorded a net loss of $3.3 million on total operating expenses of $3.3 million, both slightly improved versus 2025.
For the six months ended June 30, 2026, total operating expenses were $5.9 million compared with $7.7 million a year earlier, and the net loss narrowed to $5.8 million from $7.5 million, reflecting lower research and development spending. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents and expects its resources to fund operations through the first quarter of 2027.
The company states that existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to commence and complete clinical trials and that it does not plan to start a trial unless funding sufficient to complete that trial is secured, potentially via partnerships, out-licensing, grants, or financings.
Cadrenal Therapeutics, Inc. reoriented its pipeline by creating a unified Cardiac Acute Critical Care Franchise and starting a structured process to pursue strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets.
The company highlighted late-breaking Phase 2 data for CAD-1005 presented at the ISTH 2026 Congress, showing a greater than 25% absolute reduction in thrombotic events with a favorable safety and renal-protective baseline. CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia, has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA. The franchise also includes frunexian, an IV Factor XIa inhibitor, and tecarfarin, an oral vitamin K antagonist being advanced for chronic anticoagulation indications and rare pediatric disease protocols that the company states could potentially qualify for a Priority Review Voucher. Beyond the franchise, Cadrenal is progressing CAD-2000, an oral 12-LOX inhibitor for chronic cardiorenal inflammatory and thrombotic indications, as a companion to its IV acute care platform.
Cadrenal Therapeutics, Inc. entered into a confidential separation agreement and general release with Chief Medical Officer Dr. James J. Ferguson III, following his previously reported resignation effective July 31, 2026.
Dr. Ferguson will receive salary through the Separation Date, reimbursement of approved unreimbursed business expenses, and company payment of COBRA medical premiums for up to six (6) months after the Separation Date for himself and eligible dependents, subject to ongoing COBRA eligibility and loss of benefits if he becomes eligible for new employer coverage. The agreement includes a broad release of claims and a non-disparagement clause and becomes effective only after two separate seven-day revocation periods, one after he signs the agreement and another after he signs a second release on the Separation Date.
Cadrenal Therapeutics, Inc. reported that its Chief Medical Officer, Dr. James J. Ferguson III, has decided to resign from his position. He notified the Board on July 7, 2026, and his resignation will be effective on July 31, 2026, referred to as the Separation Date. Cadrenal is conducting a search to identify a new Chief Medical Officer to lead its medical and clinical functions. The company and Dr. Ferguson are negotiating the terms of his departure and expect to enter into a separation agreement and release at a later time.
Cadrenal Therapeutics entered a private placement with a single institutional investor, issuing 960,000 pre-funded warrants and series C-1 and C-2 warrants to purchase up to an additional 1,920,000 common shares at a combined price of $3.1249 per pre-funded warrant and accompanying warrants.
The company expects gross proceeds of about $3 million and may receive approximately $5.8 million more if the series C-1 and C-2 warrants are fully exercised for cash, for total potential proceeds of up to $8.8 million. Net proceeds are intended for working capital, and management anticipates this funding will extend its cash runway into early 2027, and into the second half of 2027 if all warrants are exercised for cash.
Pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire until fully exercised. The series C-1 and C-2 warrants carry a $3.00 exercise price, with C-1 exercisable after stockholder approval and expiring five years after key effectiveness dates, and C-2 exercisable immediately and expiring 24 months after the resale registration becomes effective. The deal includes lock-up agreements for officers and directors, registration rights with liquidated damages of 1% of invested capital per 30-day delay (capped at 6%), and placement agent compensation to H.C. Wainwright including cash fees and warrants for 62,400 shares at $3.9063 per share.
Cadrenal Therapeutics, Inc. appointed John P. Sharp as Interim Chief Financial Officer, replacing Quang X. Pham in that role while he remains Chairman and CEO. Sharp will serve through consulting firm Lohman & Associates under a Master Services Agreement and a new Statement of Work. Lohman will bill $455/hour for up to 24 hours per week of Sharp’s services. Separately, director Steven Zelenkofske resigned effective June 30, 2026, and the Board realigned its classified structure by moving director Glynn Wilson to the Class III seat, reappointing him to the Audit and Nominating and Corporate Governance Committees and adding him to the Compensation Committee. Non-employee directors receive an annual cash fee of $35,000 for Board service in 2026, plus equity awards.
Cadrenal Therapeutics is planning to seek U.S. FDA Rare Pediatric Disease Designation for tecarfarin to treat children with Kawasaki disease who develop coronary artery aneurysms and need chronic oral anticoagulation. The company highlights a dual-track portfolio: CAD-1005 as a first-in-class 12-LOX inhibitor for critical care, and tecarfarin for regional and rare indications.
If the designation is granted and tecarfarin is later approved, Cadrenal could receive a transferable Priority Review Voucher, with recent sales ranging from about $180 million to $205 million. CAD-1005 already holds Orphan Drug and Fast Track designations in the U.S. and orphan status in Europe for heparin-induced thrombocytopenia.
Cadrenal Therapeutics, Inc. reported that Chief Financial Officer Matthew K. Szot mutually agreed to transition out of his role effective May 28, 2026. Immediately afterward, the company appointed Chief Executive Officer Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer while it conducts a search for a permanent CFO.
Under a Severance Agreement dated June 3, 2026, Mr. Szot is entitled to a cash severance of $365,806.00 paid in four installments and his fiscal 2026 target cash bonus of $237,903.00 paid in two installments, all subject to standard deductions and withholdings. All of his outstanding stock options will fully vest and remain exercisable until their original expiration dates. The agreement includes a seven-day Revocation Period, a general release of claims, and a non-disparagement clause.
Cadrenal Therapeutics reported first quarter 2026 results and outlined next steps for its lead drug CAD-1005 in heparin-induced thrombocytopenia (HIT). Operating expenses fell to $2.5 million from $3.9 million a year earlier, narrowing the net loss to $2.5 million from $3.8 million.
As of March 31, 2026, the company held $2.3 million in cash and cash equivalents and later completed a $2.5 million financing to support near-term development. After receiving official End-of-Phase 2 FDA meeting minutes, Cadrenal plans a randomized, blinded, placebo-controlled Phase 3 registration trial of CAD-1005 added to standard care in HIT.
Cadrenal Therapeutics announced that it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance for a pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia (HIT). Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The company plans a randomized, blinded, placebo-controlled Phase 3 study in approximately 120 HIT patients across up to 50 clinical centers worldwide, with treatment for up to 14 days during hospitalization. The trial is intended to support a projected NDA submission in 2029.
Cadrenal Therapeutics, Inc. entered into a warrant inducement agreement with an existing holder, who agreed to exercise warrants for up to 571,430 common shares at $4.50 per share. This cash exercise is expected to provide approximately $2.5 million in gross proceeds for working capital.
In return, Cadrenal issued new unregistered Series B-1 and Series B-2 warrants, each for 571,430 shares at an exercise price of $4.50 per share, plus placement agent warrants for 37,143 shares at $5.625 per share. The company will file a Form S-3 to register the resale of the new warrant shares and agreed to short-term restrictions on issuing additional equity or registration statements.
Cadrenal Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026 to align on a proposed Phase 3 pivotal trial design.
For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million a year earlier, while general and administrative expenses were $2.4 million, down from $2.7 million. Cadrenal posted a quarterly net loss of $3.0 million, improving from a $4.2 million loss in Q4 2024.
For the full year 2025, operating expenses totaled $13.5 million and the net loss was $13.2 million, compared with a $10.7 million net loss in 2024. Cash and cash equivalents were $4.0 million as of December 31, 2025, and the company is evaluating financing and strategic alternatives to support planned clinical development.
Cadrenal Therapeutics reported new preclinical research on its first-in-class 12-lipoxygenase inhibitor CAD-1005, showing potential to address inflammation linked to obesity and Type 2 diabetes. In animal models, oral CAD-1005 (formerly VLX-1005) improved glycemic control, reduced pancreatic β-cell loss, lowered inflammatory cells in fat and pancreatic tissue, and decreased pro-inflammatory cytokines in adipose tissue.
The findings support 12-LOX as a key driver of obesity-related inflammation and suggest that selectively inhibiting this enzyme may help restore metabolic signaling and protect tissues from inflammatory damage. CAD-1005 is already in clinical development for suspected heparin-induced thrombocytopenia (HIT), where a Phase 2 trial showed reduced thrombotic events. The company is also advancing next-generation oral 12-LOX inhibitor CAD-2000 and maintains additional late-stage programs, including the anticoagulant tecarfarin and Factor XIa inhibitor frunexian.
Cadrenal Therapeutics reported Phase 2 trial results for CAD-1005 in heparin-induced thrombocytopenia. The randomized, blinded, placebo-controlled study did not meet its primary endpoint of improving platelet count recovery versus placebo on top of standard anticoagulant therapy. However, CAD-1005 achieved a greater than 25% absolute reduction in new or worsening thrombotic events compared with placebo, suggesting potential clinical benefit despite the small sample size. The company has been granted an End-of-Phase 2 meeting with the FDA in March 2026 to discuss a Phase 3 registration path for CAD-1005, which it describes as the only 12-LOX inhibitor in clinical development for this indication.
Cadrenal Therapeutics entered into a securities purchase agreement for a mixed stock and warrant financing. The company is selling 207,374 shares of common stock in a registered direct offering at $10.85 per share and issuing unregistered common warrants to purchase up to 414,748 additional shares in a concurrent private placement, for expected gross proceeds of about $2.2 million.
The common warrants have a $10.60 exercise price, are exercisable immediately, and will expire two years after the effective date of a future resale registration statement, with beneficial ownership capped between 4.99% and 9.99%. H.C. Wainwright & Co. is acting as placement agent, receiving cash fees, expense reimbursements, and warrants to buy 13,479 shares at $13.5625. The company, its directors, and officers agreed to 10-day lock-ups and short-term limits on new equity issuances and registration filings, plus a one-year ban on variable rate transactions other than a potential at-the-market program with Wainwright.
Cadrenal Therapeutics, Inc. filed a prospectus supplement supporting its existing at-the-market equity program, allowing the offer and sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co. as sales agent. These sales are made under an already effective Form S-3 shelf registration statement. As of the same date, the company has sold an aggregate of $9,386,964 of common stock under this at-the-market agreement. H.C. Wainwright is entitled to a 3.0% commission on the gross sales price of shares sold, and the company may suspend or terminate the program subject to the terms of the agreement.
Cadrenal Therapeutics (CVKD) submitted an 8-K announcing it furnished a press release with financial information for the quarter ended September 30, 2025, under Item 2.02.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed, and is not incorporated by reference into other SEC filings. The press release was issued on November 10, 2025.
Cadrenal Therapeutics, Inc. reported the outcome of its auditor ratification vote on September 24, 2025. The company disclosed vote totals for the Auditor Ratification Proposal showing 1,207,152 votes in favor, 64,913 votes against, 12,681 abstentions and 0 broker non‑votes. The filing lists Steven Zelenkofske and is signed by Quang X. Pham, Chairman and Chief Executive Officer. This item records a routine corporate governance vote approving the company's independent auditor; no financial results, material transactions, or other operational details were included in the provided text.
On August 11, 2025, Cadrenal Therapeutics, Inc. filed a Form 8-K reporting that it issued a press release containing financial information for the fiscal quarter ended June 30, 2025, furnished as Exhibit 99.1 to the report. The filing identifies the company as an emerging growth company and shows its common stock is listed on the Nasdaq Capital Market under the symbol CVKD. The filing also furnishes the cover page interactive XBRL as Exhibit 104 and was signed by Quang X. Pham, Chairman and Chief Executive Officer.
The company states the press release and Item 2.02 disclosure are furnished, not "filed" for purposes of Section 18, and will not be incorporated by reference into other SEC filings.